With its executive suite in turmoil, its flagship drug under attack and its books burdened by debt following years of drought in its R&D arm, Teva is reportedly preparing to unleash a major reorganization that will cost thousands of jobs. But after first staying mum on the subject, the Israeli pharma company now says it … Continue reading Teva denies big layoffs are planned, but will push greater efficiency and shutter floundering efforts
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed